[Results of @entity205 therapy in the early phase of XXXX ].

@entity1 @entity6 @entity12737 @entity205 @entity1723 @entity1011 @entity7138
A number of findings concerning the pathogenesis of @entity1723 have shown that an autoimmune process is responsible for the destruction of the beta-cell mass, and that a major part of this process has already occurred during the prediabetic phase of the disease. Various immunosuppressive intervention trials have, thus, recently been performed. Remission rates of between 30% and 50% in the Canadian @entity205 (CyA) pilot study prompted two placebo-controlled double-blind studies applying this medication. In the French CyA trial 122 @entity1 were followed up for 9 months. 37% of those on high-dose CyA (whole blood levels greater than 300 ng/ml) achieved total remission, compared with 16.7% of those on low-dose CyA (blood level less than 300 ng/ml) and 5% of the placebo group. The Canadian-European trial included 188 @entity1 , of whom 42 were treated in the Viennese centre. @entity6 had been diagnosed in these 42 @entity1 not more than 6 weeks previously, and the duration of their symptoms did not exceed 14 weeks. Whole blood CyA levels ranged from 400 to 800 ng/ml. In relation to short duration of symptoms and early commencement of treatment up to 10 times higher total remission rates were found in the CyA group as compared with the placebo group. In both studies similar side effects were seen. Apart from the cosmetic side effects ( @entity12737 , @entity7138 ) a decrease of 20% in @entity1011 clearance and an increase of 20% in plasma @entity1011 level seemed to be of clinical importance.(ABSTRACT TRUNCATED AT 250 WORDS)
